Innate Pharma Licenses Antibodies to Takeda for Celiac Disease Research
French biotechnology company Innate Pharma S.A. (Nasdaq: IPHA), has entered into an exclusive license agreement with Takeda, granting Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies.
The primary focus of Takeda’s research will be celiac disease, and Takeda will be responsible for the future development, manufacture and commercialization of products developed using the licensed antibodies.
Under the terms of the license agreement, Innate will receive a $5 million upfront payment.
Innate is eligible to receive up to $410m in future development, regulatory and commercial milestones if all milestones are achieved during the term of the agreement.
The agreement also stipulates royalties paid to Innate on potential net sales of any commercial product resulting from the license.
The agreement expands the application of Innate’s science beyond its oncology focus.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform. Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.